#United States #Jersey City #respiratory care #LibAirty #Synchrony Medical

Synchrony Medical Expands Nationwide

Synchrony Medical, an innovative company specializing in respiratory care technology, has announced a significant milestone in its expansion efforts. The company recently secured a $1 million investment from the New Jersey Innovation Evergreen Fund (NJIEF), which is designed to stimulate growth in promising health tech enterprises. This funding complements an earlier investment from Edge Medical Ventures, pushing the company closer to its goal of widespread commercialization of its groundbreaking LibAirty™ airway clearance system.

About LibAirty™ System

The LibAirty™ system is the first of its kind to have received FDA clearance, providing a unique approach to airway clearance that integrates guided breathing with targeted chest compressions. This technology allows patients to effectively clear their lungs through a straightforward and quick daily treatment in the comfort of their homes. It plays a vital role for individuals suffering from chronic lung conditions such as chronic obstructive pulmonary disease (COPD), bronchiectasis, and cystic fibrosis, which necessitate regular airway clearance to avert complications, minimize hospital visits, and enhance overall well-being.

Clinical studies have shown that LibAirty™ surpasses traditional airway clearance methods, offering improved sputum clearance and enhanced comfort for users, making it a necessary tool in managing chronic respiratory conditions.

Vision for the Future

Anat Shani, CEO of Synchrony Medical, expressed her vision for the company's impact on respiratory health management at home. “Our aim is to fundamentally alter how chronic lung diseases are managed remotely,” she stated. The financial backing from Edge Medical and NJIEF is expected to be instrumental in not only scaling operations in the U.S. but also in broadening the accessibility of the LibAirty™ system through various healthcare avenues such as clinics, hospitals, and homecare networks across the nation.

NJIEF, which operates as a joint initiative under the New Jersey Economic Development Authority, is committed to attracting and nurturing innovative tech companies like Synchrony Medical, thereby enhancing New Jersey's status as a hub for health technology advancements. The matching investment speaks volumes about the confidence NJIEF and Edge Medical Ventures have in Synchrony’s unique offering.

Shai Policker, Managing Partner at Edge Medical Ventures, remained optimistic about Synchrony Medical's position in the market, pointing out the significant clinical validation and practicality of the LibAirty™ system. He remarked, “We are already observing tangible signs of commercial traction and are confident that Synchrony is poised to take the lead in the airway clearance sector.”

The Path Forward

With its headquarters located in Jersey City, New Jersey, Synchrony Medical is strategically positioned within one of the most dynamic health innovation ecosystems in the country. The recent funding is expected to fuel further research and development of the LibAirty™ system, enhancing the company's offerings and ensuring that all necessary improvements are made based on user experience and clinical efficacy feedback.

In conclusion, Synchrony Medical is not only enhancing its operational capabilities and commercial outreach within the U.S. but is also shaping a new standard of care for patients living with chronic lung diseases. The company invites innovations and embraces advancements to improve respiratory health, proving that patient welfare remains at the core of their mission. For additional details about their offerings and vision, visit LibAirty Health.